COMMUNIQUÉS West-GlobeNewswire

Kriya Announces $320 Million Series D Financing to Advance Pipeline of Gene Therapies for Chronic Diseases of High Unmet Need
10/09/2025
– Proceeds to support clinical trials of Kriya’s five lead pipeline programs, as well as the Company’s R&D and manufacturing engine for new product development – RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2025 (GLOBE [...]
DeepView® System highlighted at the European Burns Association Congress
10/09/2025
DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
Catheter Precision Announces Tender Win and First Purchase Order in Croatia
10/09/2025
FORT MILL, S.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
JenaValve Announced ESC Guidelines Recognize TAVI as Class IIb Recommendation for Aortic Regurgitation
10/09/2025
IRVINE, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the newly published guidelines from [...]
Picard Announces Appointment of Two New Members to its Board of Directors
10/09/2025
Appointments strengthen Picard’s Board with proven expertise in capital markets and global MedTech leadership TUCSON, Ariz., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the [...]
Major shareholder announcement
10/09/2025
Please read the full announcement in PDF Attachments Novozymes B 04 September 2025_Final 2025_44_Major_Shareholders_Announcement
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
10/09/2025
Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical translation of the Bone Marrow Organoid technology HOUSTON, Sept. 10, [...]
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
10/09/2025
The company’s operating loss declined by 51% year-over-year, reflecting a laser focus on relentless execution and significant progress in expense reduction CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa [...]
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
10/09/2025
SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
10/09/2025
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for [...]
Wellcome Leap and Pivotal Commit $100 Million to Women’s Health Research to Deliver Breakthroughs in Years, Not Decades
10/09/2025
Partnership brings Leap’s total investment to a quarter billion dollars – advancing toward a $1 billion goal to transform outcomes for women worldwide SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Wellcome Leap, a U.S. [...]
Eleos Launches Smarter Support for Group Therapy and SUD Care
10/09/2025
New Groups capability represents the first AI solution to deliver individual speaker summaries for group therapy sessions, enabling SUD organizations to achieve documentation compliance at scale Eleos to unveil product [...]
neurocare group's Apollo TMS Therapy Devices Now Have FDA Clearance to Treat Adolescents Suffering With Major Depression
10/09/2025
Munich, Germany; Atlanta, Georgia - September 10, 2025 – neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance, today announced it has received FDA [...]
Saudi Food and Drug Authority, AAMI Partner on Medtech Best Practices
10/09/2025
SFDA and AAMI Sign Memorandum of Understanding Arlington, Virginia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation (AAMI) has signed a memorandum of understanding with [...]
KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025
10/09/2025
RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) led Saudi healthcare institutions in clinical trials, conducting 48% of all clinical trials [...]
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program
10/09/2025
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program with an IND submission expected next year This NIH grant award strongly confirms the scientific and [...]
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
10/09/2025
SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent Biologics to [...]
Les données publiées dans The New England Journal of Medicine démontrent que l’association de RYBREVANT®▼ (amivantamab) et de LAZCLUZE®▼ (lazertinib) serait susceptible de redéfinir les perspectives de survie dans le traitement de première
10/09/2025
Ce schéma thérapeutique combiné sans chimiothérapie pourrait ouvrir une nouvelle ère dans le traitement de première intention, avec une survie globale médiane prévue supérieure à quatre ans, dépassant ainsi de plus d’un [...]
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
10/09/2025
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]

Pages